Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) shares shot up 5.3% during mid-day trading on Friday after an insider bought additional shares in the company. The company traded as high as $28.72 and last traded at $28.7670. Approximately 2,926,975 shares were traded during trading, an increase of 4% from the average session volume of 2,816,803 shares. The stock had previously closed at $27.31.
Specifically, Director Michael Hayden purchased 5,000 shares of the firm’s stock in a transaction on Tuesday, November 10th. The stock was purchased at an average cost of $29.64 per share, for a total transaction of $148,200.00. Following the completion of the purchase, the director directly owned 27,000 shares in the company, valued at $800,280. This trade represents a 22.73% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Analyst Ratings Changes
IONS has been the topic of a number of recent analyst reports. UBS Group began coverage on Ionis Pharmaceuticals in a report on Thursday, October 15th. They set a “buy” rating and a $88.00 target price on the stock. Barclays dropped their price target on Ionis Pharmaceuticals from $90.00 to $85.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 9th. BMO Capital Markets raised Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price target for the company from $54.00 to $66.00 in a report on Thursday, October 22nd. Morgan Stanley reduced their price objective on shares of Ionis Pharmaceuticals from $104.00 to $75.00 and set an “overweight” rating for the company in a research report on Tuesday, November 10th. Finally, Guggenheim reduced their price objective on shares of Ionis Pharmaceuticals from $89.00 to $80.00 and set a “buy” rating for the company in a research report on Tuesday, September 15th. Nineteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $75.71.
Key Ionis Pharmaceuticals News
Here’s some of the latest news about IONS:
- Positive Sentiment: Two-year DAWNZERA data presented at the ACAAI meeting supported durable efficacy and disease control for hereditary angioedema, adding clinical evidence for the drug. Wells Fargo also rated Ionis a Buy. DAWNZERA long-term data Wells Fargo rating
- Negative Sentiment: Ionis reportedly cut its full-year TRYNGOLZA sales outlook by roughly half after third-quarter sales reached just $9.3 million. The sales shortfall prompted investor-law-firm investigations, creating additional legal and reputational overhang. Investor investigation notice Wolf Popper investigation
- Negative Sentiment: Several firms—including Morgan Stanley, Needham, HC Wainwright, Oppenheimer and Goldman Sachs—cut price expectations; a separate analyst downgrade was associated with a sharp recent decline in the shares. Artisan Partners also said its small-cap growth strategy exited Ionis following sequential Phase 3 setbacks. Morgan Stanley price target Artisan Partners exit
Ionis Pharmaceuticals Price Performance
The company has a debt-to-equity ratio of 3.42, a quick ratio of 7.73 and a current ratio of 5.43. The company has a market cap of $4.84 billion, a price-to-earnings ratio of -8.75 and a beta of 0.43. The business has a fifty day moving average price of $43.65 and a 200 day moving average price of $64.57.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.23) by $0.57. The company had revenue of $242.72 million during the quarter, compared to the consensus estimate of $178.17 million. Ionis Pharmaceuticals had a negative net margin of 56.98% and a negative return on equity of 120.62%. The company’s revenue for the quarter was up 54.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.80) earnings per share. As a group, research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.59 earnings per share for the current year.
Institutional Investors Weigh In On Ionis Pharmaceuticals
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Pictet Asset Management Holding SA increased its holdings in Ionis Pharmaceuticals by 21.7% during the third quarter. Pictet Asset Management Holding SA now owns 1,944,020 shares of the company’s stock worth $87,249,000 after buying an additional 347,022 shares during the last quarter. Alyeska Investment Group L.P. boosted its stake in Ionis Pharmaceuticals by 199.7% in the second quarter. Alyeska Investment Group L.P. now owns 1,417,916 shares of the company’s stock valued at $112,427,000 after acquiring an additional 944,766 shares during the last quarter. GW&K Investment Management LLC boosted its stake in Ionis Pharmaceuticals by 79.6% in the third quarter. GW&K Investment Management LLC now owns 1,341,315 shares of the company’s stock valued at $59,890,000 after acquiring an additional 594,349 shares during the last quarter. Groupama Asset Managment boosted its stake in Ionis Pharmaceuticals by 7.5% in the first quarter. Groupama Asset Managment now owns 824,540 shares of the company’s stock valued at $61,915,000 after acquiring an additional 57,651 shares during the last quarter. Finally, Bank of America Corp DE bought a new position in shares of Ionis Pharmaceuticals during the 2nd quarter valued at approximately $62,718,000. 93.86% of the stock is owned by institutional investors.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.
See Also
- Five stocks we like better than Ionis Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
